본문 바로가기

Entecavir versus tenofovir on the recurrence of hepatitis B-related HCC after liver transplantation: A multicenter observational study

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
LIVER TRANSPLANTATION29(12) · pp.1272 · 2023
피인용
Web of Science 0Scopus 2
FWCI (Scopus)
0.23
JCR IF
JCR 2022 5
ISSN
1527-6465

저자

  1. Kim, Deok-Gie제1저자Yonsei Univ, Coll Med, Res Inst Transplantat, Dept Surg, 50-1 Yonsei Ro, Seoul, South Korea
  2. Choi, YoungrokSeoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Surg, Seoul, South Korea
  3. Rhu, JinsooSungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, Seoul, South Korea
  4. Hwang, ShinUniv Ulsan, Coll Med, Asan Med Ctr, Dept Surg, Seoul, South Korea
  5. You, Young KyoungCatholic Univ Korea, Coll Med, Dept Surg, Seoul, South Korea
  6. Kim, Dong-SikKorea Univ, Coll Med, Dept Surg, Div HBP Surg & Liver Transplantat, Seoul, South Korea
  7. Nah, Yang WonUniv Ulsan, Ulsan Univ Hosp, Dept Surg, Coll Med, Ulsan, South Korea
  8. Kim, Bong-WanAjou Univ, Sch Med, Dept Liver Transplantat & Hepatobiliary Surg, Suwon, South Korea
  9. Cho, Jai YoungSeoul Natl Univ, Coll Med, Dept Surg, Bundang Hosp, Songnam, South Korea
  10. Kang, Koo JeongKeimyung Univ, Sch Med, Dongsan Med Ctr, Dept Surg, Daegu, South Korea
  11. Yang, Jae DoJeonbuk Natl Univ Hosp, Dept Surg, Jeonju, South Korea
  12. Choi, DonglakCatholic Univ Daegu, Dept Surg, Daegu, South Korea
  13. Joo, Dong JinYonsei Univ, Coll Med, Res Inst Transplantat, Dept Surg, 50-1 Yonsei Ro, Seoul, South Korea
  14. Kim, Myoung SooYonsei Univ, Coll Med, Res Inst Transplantat, Dept Surg, 50-1 Yonsei Ro, Seoul, South Korea
  15. 류제호교신저자Pusan Natl Univ, Yangsan Hosp, Sch Med, Dept Surg, Pusan, South Korea
  16. Lee, Jae Geun교신저자Yonsei Univ, Coll Med, Res Inst Transplantat, Dept Surg, 50-1 Yonsei Ro, Seoul, South Korea

초록

Considerable controversy exists regarding the superiority of tenofovir disoproxil fumarate (TDF) over entecavir (ETV) for reducing the risk of HCC. This study aimed to compare outcomes of ETV versus TDF after liver transplantation (LT) in patients with HBV-related HCC. We performed a multicenter observational study using data from the Korean Organ Transplantation Registry. A total of 845 patients who underwent LT for HBV-related HCC were divided into 2 groups according to oral nucleos(t)ide analogue used for HBV prophylaxis post-LT: ETV group (n = 393) and TDF group (n = 452). HCC recurrence and overall death were compared in naive and propensity score (PS)-weighted populations, and the likelihood of these outcomes according to the use of ETV or TDF were analyzed with various Cox models. At 1, 3, and 5 years, the ETV and TDF groups had similar HCC recurrence-free survival (90.7%, 85.6%, and 84.1% vs. 90.9%, 84.6%, and 84.2%, respectively, p = 0.98) and overall survival (98.4%, 94.7%, and 93.5% vs. 99.3%, 95.8%, and 94.9%, respectively, p = 0.48). The propensity score-weighted population showed similar results. In Cox models involving covariates adjustment, propensity score-weighting, competing risk regression, and time-dependent covariates adjustment, both groups showed a similar risk of HCC recurrence and overall death. In subgroup analyses stratified according to HCC burden (Milan criteria, Up-to-7 criteria, French alpha-fetoprotein risk score), pretransplantation locoregional therapy, and salvage LT, neither ETV nor TDF was superior. In conclusion, ETV and TDF showed mutual noninferiority for HCC outcomes when used for HBV prophylaxis after LT.

키워드

HEPATOCELLULAR-CARCINOMA RECURRENCEDISOPROXIL FUMARATENUCLEOSIDEANALOGSNUCLEOTIDESAFETYRISK

식별자

Scopus EID
2-s2.0-85176508930
WoS UID
001075312900001